News

The accelerated approval for the Polivy, BR combination is for treatment of adult patients with DLBCL whose condition is either relapsed or refractory (R/R) and had been subjected

In the study, PPC-06 met both co-primary endpoints i.e. PASI-75 and IGA scores of 0 or 1 with at least a 2-point reduction from baseline, after 24 weeks

The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments. Both

Tilos Therapeutics is involved in the development of therapeutics, which targets the latent TGFβ complex to treat cancer, fibrosis and autoimmune diseases. TGFβ is a potent cytokine supposed

As per the terms of the deal, Theramex will have exclusive commercialisation rights for BIJUVA and IMVEXXY outside the US with the exception of Canada and Israel where

“We are thrilled to be advancing this strategic alliance with Janssen R&D for connecting biological information to disease condition and therapeutic mechanisms. By pairing the unique data science

All six patients were recruited and treated under this protocol. All primary safety objectives have been achieved at the midpoint in all study participants. As such, the protocol

In January 2017, Acucela had received orphan drug designation from the US Food and Drug Administration (FDA) for emixustat to treat Stargardt disease. Stargardt disease is a rare

The Calquence, obinutuzumab combination registered a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) during the trial, which was the primary endpoint. This was in comparison to the